ARCHIVES

New Safety Concerns On ESAs Prompt FDA To Consult ODAC Again.

This article is from The Cancer Letter archive.

Vol. 34 No. 01 | January 11, 2008

Download PDF Visit The Full Archive

Related Articles

Sponsors Withdraw Indications for Iressa, Celebrex

February 11, 2011

IMRT Less Toxic Than 3D-CRT In Localized Prostate Cancer

October 28, 2011

In Brief: NCI Grants Up Fourfold Since 1970; Rappaport, Jensen Speakers At Annual AACR,ASCO Meeting

April 25, 1975

FDA Officials Lists ‘Lessons’ Learned Working With AIDS Patient Organizations

August 14, 1992

In Brief: Hospices Urges To Develop Program For AIDs Victims; Companies Give $25,5000 To NCI Fund

October 25, 1985

St. Jude Director Cites Poor Housing’s Toll on Children, March 28, 1971

May 19, 2021